Huntington's disease (HD) is a neurodegenerative disorder causing motor, cognitive, and psychiatric impairments, with the striatum being the most affected brain region. However, the role of other regions, such as the hippocampus, in HD remains less understood.
Objective
Here, we study the comparative impact of enhanced mHTT aggregation and neuropathology in the striatum and hippocampus of two HD mouse models.
Methods
We utilized the zQ175 as a control HD mouse model and the Q175DN mice lacking the PGK-Neomycin cassette generated in house. We performed a comparative characterization of the neuropathology between zQ175 and Q175DN mice in the striatum and the hippocampus by assessing HTT aggregation, neuronal and glial pathology, chaperone expression, and synaptic density.
Results
We showed that Q175DN mice presented enhanced mHTT aggregation in both striatum and hippocampus compared to zQ175. Striatal neurons showed a greater susceptibility to enhanced accumulation of mHTT in Q175DN. On the contrary, no signs of hippocampal pathology were found in zQ175 and absence of hippocampal pathology persisted in Q175DN mice despite higher levels of mHTT. In addition, Q175DN hippocampus presented increased synaptic density, decreased Iba1+ microglia density and enhanced HSF1 levels in specific subregions of the hippocampus compared to zQ175.
Conclusions
Q175DN mice are a valuable tool to understand the fundamental susceptibility differences to mHTT toxicity between striatal neurons and other neuronal subtypes. Furthermore, our findings also suggest that cognitive deficits observed in HD animals might arise from either striatum dysfunction or other regions involved in cognitive processes but not from hippocampal degeneration.
MacDonaldMEAmbroseCMDuyaoMP, et al.A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell1993; 72: 971–983.
2.
BatesG. Huntingtin aggregation and toxicity in Huntington's disease. Lancet2003; 361: 1642–1644.
3.
ArrasateMFinkbeinerS. Protein aggregates in Huntington's disease. Exp Neurol2012; 238: 1–11.
HanIYouYKordowerJH, et al.Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem2010; 113: 1073–1091.
6.
MorigakiRGotoS. Striatal vulnerability in Huntington’s disease: neuroprotection versus neurotoxicity. Brain Sci2017; 7: 63.
7.
GravelandGAWilliamsRSDiFigliaM. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science1985; 227: 770–773.
8.
GotoSHiranoARojas-CoronaRR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol1989; 25: 298–304.
9.
VonsattelJPMyersRHStevensTJ, et al.Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol1985; 44: 559–577.
10.
FerranteRJKowallNWBealMF, et al.Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol1987; 46: 12–27.
11.
Cleret de LangavantLFénelonGBenistyS, et al.Awareness of memory deficits in early stage Huntington's disease. PLoS One2013; 8: e61676.
12.
MontoyaAPelletierMMenearM, et al.Episodic memory impairment in Huntington's disease: a meta-analysis. Neuropsychologia2006; 44: 1984–1994.
13.
PaulsenJS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep2011; 11: 474–483.
14.
HarringtonDLSmithMMZhangY, et al.Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry2012; 83: 612–619.
15.
EppingEAKimJICraufurdD, et al.Longitudinal psychiatric symptoms in prodromal Huntington's disease: a decade of data. Am J Psychiatry2016; 173: 184–192.
16.
SquireLRKnowltonBMusenG. The structure and organization of memory. Annu Rev Psychol1993; 44: 453–495.
17.
SnowdenJS. The neuropsychology of Huntington's disease. Arch Clin Neuropsychol2017; 32: 876–887.
SolomonACStoutJCJohnsonSA, et al.Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia2007; 45: 1767–1776.
20.
PillonBDeweerBAgidY, et al.Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol1993; 50: 374–379.
21.
ScimecaJMBadreD. Striatal contributions to declarative memory retrieval. Neuron2012; 75: 380–392.
22.
TricomiEFiezJA. Information content and reward processing in the human striatum during performance of a declarative memory task. Cogn Affect Behav Neurosci2012; 12: 361–372.
23.
NessHTFolvikLSneveMH, et al.Reduced hippocampal-striatal interactions during formation of durable episodic memories in aging. Cereb Cortex2022; 32: 2358–2372.
24.
BalleineBWPeakJMatamalesM, et al.The dorsomedial striatum: an optimal cellular environment for encoding and updating goal-directed learning. Curr Opin Behav Sci2021; 41: 38–44.
25.
PoulterSLKosakiYSandersonDJ, et al.Spontaneous object-location memory based on environmental geometry is impaired by both hippocampal and dorsolateral striatal lesions. Brain Neurosci Adv2020; 4: 2398212820972599.
26.
DoellerCFKingJABurgessN. Parallel striatal and hippocampal systems for landmarks and boundaries in spatial memory. Proc Natl Acad Sci U S A2008; 105: 5915–5920.
27.
BirdCMBurgessN. The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci2008; 9: 182–194.
28.
BurgessNMaguireEAO'KeefeJ. The human hippocampus and spatial and episodic memory. Neuron2002; 35: 625–641.
SmithEJSathasivamKLandlesC, et al.Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches. Brain Commun2023; 5: fcad010.
31.
LiHLiSHYuZX, et al.Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci2001; 21: 8473–8481.
32.
BegetiFSchwabLCMasonSL, et al.Hippocampal dysfunction defines disease onset in Huntington's disease. J Neurol Neurosurg Psychiatry2016; 87: 975–981.
33.
RosasHDKoroshetzWJChenYI, et al.Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology2003; 60: 1615–1620.
34.
HoAKSahakianBJBrownRG, et al.Profile of cognitive progression in early Huntington's disease. Neurology2003; 61: 1702–1706.
MenalledLBKudwaAEMillerS, et al.Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One2012; 7: e49838.
37.
WheelerVCWhiteJKGutekunstCA, et al.Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet2000; 9: 503–513.
38.
MenalledLBSisonJDDragatsisI, et al.Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol2003; 465: 11–26.
39.
NaverBStubCMøllerM, et al.Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience2003; 122: 1049–1057.
40.
SunZDel MarNMeadeC, et al.Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease. Neurobiol Dis2002; 11: 369–385.
41.
PengQWuBJiangM, et al.Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 knock-in mouse model of Huntington's disease. PLoS One2016; 11: e0148839.
42.
YuDZarateNWhiteA, et al.CK2 Alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington's disease. Acta Neuropathol Commun2022; 10: 83.
43.
HäggkvistJTóthMTariL, et al.Longitudinal small-animal PET imaging of the zQ175 mouse model of Huntington disease shows in vivo changes of molecular targets in the striatum and cerebral cortex. J Nucl Med2017; 58: 617–622.
44.
GuXRichmanJLangfelderP, et al.Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice. Neuron2022; 110: 1173–1192. e1177.
45.
SouthwellALSmith-DijakAKayC, et al.An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum Mol Genet2016; 25: 3654–3675.
46.
WilkieCMBarnesJRBensonCM, et al.Hippocampal synaptic dysfunction in a mouse model of Huntington disease is not alleviated by ceftriaxone treatment. eNeuro2020; 7: ENEURO.0440–19.2020.
47.
QuirionJGParsonsMP. The onset and progression of hippocampal synaptic plasticity deficits in the Q175FDN mouse model of Huntington disease. Front Cell Neurosci2019; 13: 326.
48.
SimirskiiVNLeeRSWawrousekEF, et al.Inbred FVB/N mice are mutant at the cp49/Bfsp2 locus and lack beaded filament proteins in the lens. Invest Ophthalmol Vis Sci2006; 47: 4931–4934.
49.
FarleySJMcKayBMDisterhoftJF, et al.Reevaluating hippocampus-dependent learning in FVB/N mice. Behav Neurosci2011; 125: 871–878.
50.
KochETChengJRamandiD, et al.Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight. BMC Biol2024; 22: 121.
51.
Vidas-GuscicNvan RijswijkJVan AudekerkeJ, et al.Diffusion MRI marks progressive alterations in fiber integrity in the zQ175DN mouse model of Huntington's disease. Neurobiol Dis2024; 193: 106438.
52.
BertoglioDVerhaegheJWyffelsL, et al.Synaptic vesicle glycoprotein 2A is affected in the central nervous system of mice with Huntington disease and in the brain of a human with Huntington disease postmortem. J Nucl Med2022; 63: 942–947.
53.
HuhtalaTPoutiainenPRytkönenJ, et al.Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors. EJNMMI Radiopharm Chem2019; 4: 20.
54.
WuJMöhleLBrüningT, et al.A novel Huntington's disease assessment platform to support future drug discovery and development. Int J Mol Sci2022; 23: 14763.
55.
NaydenovAVSepersMDSwinneyK, et al.Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol Dis2014; 71: 140–150.
56.
HisatsuneCOgawaNMikoshibaK. Striatum-specific expression of Cre recombinase using the Gpr88 promoter in mice. Transgenic Res2013; 22: 1241–1247.
57.
Gomez-PastorRBurchfielETNeefDW, et al.Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington's disease. Nat Commun2017; 8: 14405.
58.
BrownTGThayerMNVanTreeckJG, et al.Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease. Front Cell Neurosci2023; 17: 1094503.
59.
RavaliaASLauJBarronJC, et al.Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. Neurobiol Dis2021; 152: 105293.
60.
ManskyRHGreguskeEAYuD, et al.Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease. Cell Rep2023; 42: 112198.
61.
LiHLiSHJohnstonH, et al.Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet2000; 25: 385–389.
62.
GutekunstCALiSHYiH, et al.Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci1999; 19: 2522–2534.
63.
WangCEZhouHMcGuireJR, et al.Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol2008; 181: 803–816.
64.
CartyNBersonNTillackK, et al.Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study. PLoS One2015; 10: e0123527.
65.
MorelliKHWuQGosztylaML, et al.An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models. Nat Neurosci2023; 26: 27–38.
66.
SönmezAMustafaRRyllST, et al. Nucleolar stress controls mutant Huntington toxicity and monitors Huntington's disease progression. Cell Death Dis2021; 12: 1139.
67.
PapadopoulouASGomez-ParedesCMasonMA, et al.Extensive expression analysis of Htt transcripts in brain regions from the zQ175 HD mouse model using a QuantiGene Multiplex assay. Sci Rep2019; 9: 16137.
68.
van DellenAWelchJDixonRM, et al.N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport2000; 11: 3751–3757.
69.
Luthi-CarterRStrandAPetersNL, et al.Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet2000; 9: 1259–1271.
70.
BibbJAYanZSvenningssonP, et al.Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A2000; 97: 6809–6814.
71.
Diaz-CastroBGangwaniMRYuX, et al.Astrocyte molecular signatures in Huntington's disease. Sci Transl Med2019; 11: eaaw8546.
72.
KhakhBSBeaumontVCachopeR, et al.Unravelling and exploiting astrocyte dysfunction in Huntington's disease. Trends Neurosci2017; 40: 422–437.
73.
HolEMPeknyM. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol2015; 32: 121–130.
74.
EngLFVanderhaeghenJJBignamiA, et al.An acidic protein isolated from fibrous astrocytes. Brain Res1971; 28: 351–354.
75.
SappEKegelKBAroninN, et al.Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol2001; 60: 161–172.
76.
PaveseNGerhardATaiYF, et al.Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology2006; 66: 1638–1643.
77.
TurmaineMRazaAMahalA, et al.Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A2000; 97: 8093–8097.
78.
MaLMortonAJNicholsonLFB. Microglia density decreases with age in a mouse model of Huntington's disease. Glia2003; 43: 274–280.
79.
FranciosiSRyuJKShimY, et al.Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis2012; 45: 438–449.
80.
SavageJCSt-PierreMKCarrierM, et al.Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology. J Neuroinflammation2020; 17: 98.
81.
ItoDImaiYOhsawaK, et al.Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res1998; 57: 1–9.
82.
ZarateNGundryKYuD, et al.Neurochemical correlates of synapse density in a Huntington's disease mouse model. J Neurochem2023; 164: 226–241.
83.
DengYPWongTBricker-AnthonyC, et al.Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice. Neurobiol Dis2013; 60: 89–107.
84.
CepedaCHurstRSCalvertCR, et al.Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci2003; 23: 961–969.
85.
ParievskyAMooreCKamdjouT, et al.Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease. Neurobiol Dis2017; 108: 29–44.
86.
WiltonDKMastroKHellerMD, et al.Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease. Nat Med2023; 29: 2866–2884.
87.
ZarateNIntiharTAYuD, et al.Heat shock factor 1 directly regulates postsynaptic scaffolding PSD-95 in aging and Huntington's disease and influences striatal synaptic density. Int J Mol Sci2021; 22: 13113.
88.
MatamalesMSkrbisZHatchRJ, et al.Aging-related dysfunction of striatal cholinergic interneurons produces conflict in action selection. Neuron2016; 90: 362–373.
89.
RotheTDelianoMWójtowiczAM, et al.Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice. Neuroscience2015; 311: 519–538.
90.
SmithGARochaEMMcLeanJR, et al.Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet2014; 23: 4510–4527.
91.
WoelfleSBoeckersTM. Layer-specific vesicular glutamate transporter 1 immunofluorescence levels delineate all layers of the human hippocampus including the stratum lucidum. Front Cell Neurosci2021; 15: 789903.
92.
HerzogETakamoriSJahnR, et al.Synaptic and vesicular co-localization of the glutamate transporters VGLUT1 and VGLUT2 in the mouse hippocampus. J Neurochem2006; 99: 1011–1018.
LabbadiaJNovoselovSSBettJS, et al.Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain2012; 135: 1180–1196.
95.
ArrasateMMitraSSchweitzerES, et al.Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature2004; 431: 805–810.
96.
ReinerADel MarNDengYP, et al.R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J Comp Neurol2007; 505: 603–629.
97.
SlowEJGrahamRKOsmandAP, et al.Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A2005; 102: 11402–11407.
98.
RübUVonsattelJPHeinsenH, et al.The meuropathology of Huntingtońs disease: classical findings, recent developments and correlation to functional neuroanatomy. Adv Anat Embryol Cell Biol2015; 217: 1–146.
99.
NiccoliniFHaiderSReis MarquesT, et al.Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain2015; 138: 3016–3029.
100.
PaulBDSbodioJIXuR, et al.Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature2014; 509: 96–100.
101.
SubramaniamSSixtKMBarrowR, et al.Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science2009; 324: 1327–1330.
102.
SaudouFFinkbeinerSDevysD, et al.Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell1998; 95: 55–66.
103.
LiuYF. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem1998; 273: 28873–28877.
104.
SpargoEEverallIPLantosPL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry1993; 56: 487–491.
105.
HallidayGMMcRitchieDAMacdonaldV, et al.Regional specificity of brain atrophy in Huntington's disease. Exp Neurol1998; 154: 663–672.
106.
WilkesFAJakabekDWalterfangM, et al.Hippocampal morphology in Huntington's disease, implications for plasticity and pathogenesis: the IMAGE-HD study. Psychiatry Res Neuroimaging2023; 335: 111694.
107.
YounesLRatnanatherJTBrownT, et al.Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp2014; 35: 792–809.
108.
SharpAHLoevSJSchillingG, et al.Widespread expression of Huntington's disease gene (IT15) protein product. Neuron1995; 14: 1065–1074.
109.
MangiariniLSathasivamKMahalA, et al.Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet1997; 15: 197–200.
110.
KennedyLEvansEChenCM, et al.Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet2003; 12: 3359–3367.
111.
GonitelRMoffittHSathasivamK, et al.DNA Instability in postmitotic neurons. Proc Natl Acad Sci U S A2008; 105: 3467–3472.
112.
LeeJMPintoRMGillisT, et al.Quantification of age-dependent somatic CAG repeat instability in hdh CAG knock-in mice reveals different expansion dynamics in striatum and liver. PLoS One2011; 6: e23647.
113.
SwamiMHendricksAEGillisT, et al.Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet2009; 18: 3039–3047.
114.
Ruiz de SabandoACiosiMGalbeteA, et al.Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype. Eur J Hum Genet2024; 32: 770–778.
115.
YangWDunlapJRAndrewsRB, et al.Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet2002; 11: 2905–2917.
116.
MaheshwariMBhutaniSDasA, et al.Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease. Hum Mol Genet2014; 23: 2737–2751.
117.
Van RaamsdonkJMPearsonJSlowEJ, et al.Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci2005; 25: 4169–4180.
118.
GiraltASaavedraACarretónO, et al.Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum Mol Genet2011; 20: 4232–4247.
119.
Vogel-CierniaAWoodMA. Examining object location and object recognition memory in mice. Curr Protoc Neurosci2014; 69: 8.31.31–38.31.17.
120.
BiroliniGValenzaMOttonelliI, et al.Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease. Pharmacol Res2023; 194: 106823.
121.
AntunesMBialaG. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process2012; 13: 93–110.
122.
HogeJKesnerR. Role of CA3 and CA1 subregions of the dorsal hippocampus on temporal processing of objects. Neurobiol Learn Mem2007; 88: 225–231.
123.
LeeASAndréJMPittengerC. Lesions of the dorsomedial striatum delay spatial learning and render cue-based navigation inflexible in a water maze task in mice. Front Behav Neurosci2014; 8: 42.
124.
GoodroeSCStarnesJBrownTI. The complex nature of hippocampal-striatal interactions in spatial navigation. Front Hum Neurosci2018; 12: 250.
125.
VoermansNCPeterssonKMDaudeyL, et al.Interaction between the human hippocampus and the caudate nucleus during route recognition. Neuron2004; 43: 427–435.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
